Search results
Results from the Health.Zone Content Network
The COVID-19 vaccination campaign in the United States is an ongoing mass immunization campaign for the COVID-19 pandemic in the United States.The Food and Drug Administration (FDA) first granted emergency use authorization to the Pfizer–BioNTech vaccine on December 10, 2020, and mass vaccinations began four days later.
Pfizer–BioNTech COVID-19 vaccine A vial of the Pfizer–BioNTech COVID‑19 vaccine for the U.S. market Vaccine description Target SARS-CoV-2 Vaccine type mRNA Clinical data Trade names Comirnaty Other names BNT162b2, COVID-19 mRNA vaccine (nucleoside-modified), COVID-19 Vaccine (mRNA) AHFS / Drugs.com Monograph MedlinePlus a621003 License data EU EMA: by INN US DailyMed: Pfizer-BioNTech ...
Sweden is a part of the European Union cooperation for the purchase of COVID-19 vaccines. According to this agreement, Sweden will have access to 6 million vaccine doses. According to the Prime Minister Stefan Löfven, Sweden expected to get sufficient number of COVID-19 vaccines to immunise around one-fifth of the population by April 2021.
The vaccine should slow the spread of COVID-19 around the world. Fewer people should get sick, and more lives can be saved. The Pfizer, Moderna, and Novavax vaccines have been shown to be at least ...
A COVID‑19 vaccine is a vaccine intended to provide acquired immunity against severe acute respiratory syndrome coronavirus 2 , the virus that causes coronavirus disease 2019 . Prior to the COVID‑19 pandemic , an established body of knowledge existed about the structure and function of coronaviruses causing diseases like severe acute ...
The Moderna COVID‑19 vaccine, sold under the brand name Spikevax, is a COVID-19 vaccine developed by the American company Moderna, the United States National Institute of Allergy and Infectious Diseases (NIAID), and the Biomedical Advanced Research and Development Authority (BARDA). Depending on the jurisdiction, it is authorized for use in ...
In February 2021, Novavax partnered with Takeda to manufacture the vaccine in Japan, where its COVID‑19 vaccine candidate is known as TAK-019. [54] Novavax signed an agreement with Serum Institute of India for mass scale production for developing and low-income countries. [55]
In April 2021, the vaccine was [needs update] a key component of the WHO backed COVAX (COVID-19 Vaccines Global Access) program, with the WHO, the EMA, and the MHRA continuing to state that the benefits of the vaccine outweigh any possible side effects. [needs update]